Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
Open Access
- 1 January 2011
- journal article
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 5, CMO.S6085-156
- https://doi.org/10.4137/cmo.s6085
Abstract
Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. This compound with amphoteric properties was designed in the former Germany Democratic Republic in 1960s and re-discovered in 1990s with multiple successive well-designed studies. Bendamustine possesses a unique mechanism of action with potential antimetabolite properties, and only partial cross-resistance with other alkylators. Used in combination with rituximab in vitro, bendamustine shows synergistic effects against various leukemia and lymphoma cell lines. In clinical studies, bendamustine plus rituximab is highly effective in patients with relapsed-refractory indolent lymphoma, inducing remissions in 90% or more and a median progression-free survival of 23–24 months. The optimal dosing and schedule of bendamustine administration is largely undecided and varies among studies. Results of ongoing trials and dose-finding studies will help to further help ascertain the optimal place of bendamustine in the management of indolent NHL.Keywords
This publication has 56 references indexed in Scilit:
- The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaBlood, 2011
- Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaCancer Science, 2010
- Multicenter phase II study of bendamustine for relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphomaCancer Science, 2010
- Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphomaCancer, 2009
- Improvements in Survival After Follicular Lymphoma by Race/Ethnicity and Socioeconomic Status: A Population-Based StudyJournal of Clinical Oncology, 2009
- Follicular Lymphoma in the United States: First Report of the National LymphoCare StudyJournal of Clinical Oncology, 2009
- A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumoursBritish Journal of Cancer, 2007
- Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)Zeitschrift für Krebsforschung und Klinische Onkologie, 2005
- 131I-Tositumomab Therapy as Initial Treatment for Follicular LymphomaThe New England Journal of Medicine, 2005
- High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomasZeitschrift für Krebsforschung und Klinische Onkologie, 2002